Drugs Containing Excipient (Inactive Ingredient) IRON OXIDES

« Back to Dashboard

Generic drugs containing IRON OXIDES excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	felodipine	50090-1124	IRON OXIDES
A-S Medication Solutions	rosuvastatin calcium	50090-2447	IRON OXIDES
A-S Medication Solutions	loperamide hydrochloride	50090-7398	IRON OXIDES
Allegiant Health	esomeprazole magnesium capsule, delayed release	69168-472	IRON OXIDES

Iron Oxides Pharmaceutical Excipient Market: Dynamics, Financial Trajectory, Regulation, and Supply Risks

Last updated: September 13, 2026

Iron oxides are inorganic colorants used in pharmaceutical tablets, capsules, coatings, and some topical products. The market is driven by finished-dose manufacturing volumes, colorant substitution, regulatory compliance, and the availability of high-purity synthetic grades. Pharmaceutical demand is small relative to construction, coatings, plastics, and pigments, but it commands higher quality and documentation requirements.

The pharmaceutical iron oxide market has limited direct patent protection. Commercial value depends more on manufacturing qualification, impurity control, regulatory files, customer approvals, and supply reliability than on exclusivity rights. Public financial reporting generally combines pharmaceutical pigments with broader pigment or specialty-chemical businesses, so a precise global revenue figure for pharmaceutical-grade iron oxides is not publicly disclosed.

What are pharmaceutical iron oxides and how are they used?

Pharmaceutical iron oxides are colorants based primarily on iron(III) oxide, hydrated iron(III) oxide, and mixed-valence iron oxides.

Colorant	Typical chemical identity	Common appearance	Pharmaceutical use
Red iron oxide	Iron(III) oxide, Fe2O3	Red to reddish-brown	Tablet coatings, capsule shells, identification
Yellow iron oxide	Hydrated iron(III) oxide, commonly FeO(OH)·nH2O	Yellow to brown-yellow	Film coatings, tablets, suspensions
Black iron oxide	Mixed iron oxide, commonly Fe3O4	Black	Tablet coatings, capsule shells
Brown blends	Controlled mixtures of red, yellow, and black grades	Brown	Brand-color matching and dose differentiation

Iron oxides are usually used as color additives rather than as functional excipients such as binders, fillers, disintegrants, or controlled-release polymers. They improve product identification, support light protection in some formulations, and help manufacturers distinguish dosage strengths.

Pharmaceutical applications include:

• Film-coated immediate-release tablets.
• Hard gelatin and vegetarian capsule shells.
• Sugar-coated tablets.
• Chewable tablets and lozenges.
• Topical creams, ointments, and dermatological products.
• Oral suspensions and selected liquid formulations.
• Veterinary dosage forms.

The concentration is generally low, which limits direct material consumption per dose. Demand is therefore linked more closely to the number of colored products and manufacturing sites than to active pharmaceutical ingredient volume.

What regulatory standards apply to pharmaceutical iron oxides?

Iron oxide colorants must meet applicable pharmacopeial, food-additive, and drug-product requirements in each target market.

United States FDA status

In the United States, synthetic iron oxides are permitted for certain drug uses under FDA color-additive regulations. The applicable provisions include 21 C.F.R. §§ 73.200 and 73.1200, depending on the specific colorant and use category (U.S. Food and Drug Administration, 2024a).

Iron oxides also appear in the FDA Inactive Ingredient Database for approved drug products. The database records prior use by route, dosage form, and maximum potency, but it does not itself constitute a blanket approval for every formulation or route (U.S. Food and Drug Administration, 2024b).

Relevant quality expectations include:

• Identity and assay.
• Heavy-metal and elemental-impurity control.
• Microbial quality where applicable.
• Particle-size distribution.
• Specific surface area and dispersion behavior.
• Residual salts and process impurities.
• Batch-to-batch color consistency.
• Compliance with current good manufacturing practice.

European Union and other markets

In the European Union, iron oxides and hydroxides are recognized food and pharmaceutical colorants under the applicable E-number framework, particularly E172. Pharmaceutical manufacturers must still demonstrate suitability for the intended medicinal product and comply with European Pharmacopoeia requirements where applicable (European Commission, 2024).

Global suppliers often maintain separate documentation packages for:

• United States drug products.
• European medicines.
• Japan’s pharmaceutical market.
• China’s National Medical Products Administration framework.
• Latin American and Middle Eastern registrations.

The regulatory burden is higher for pharmaceutical grades than for industrial pigments because manufacturers must provide traceability, change-control support, impurity data, and audit access.

What patents protect pharmaceutical iron oxides?

Most iron oxide patent activity concerns manufacturing processes, pigment morphology, surface treatment, dispersion, and end-use formulations. The base compounds are established inorganic materials and are not protected by meaningful composition-of-matter exclusivity.

Patent categories include:

Patent category	Typical claim focus	Commercial relevance
Synthesis	Precipitation, oxidation, calcination, and crystallization	Controls purity, color, yield, and cost
Particle engineering	Particle size, morphology, surface area, and agglomeration	Improves dispersion and coating performance
Surface treatment	Silica, alumina, polymeric, or other coatings	Supports stability and formulation compatibility
Formulation	Tablet coatings, cosmetic systems, and topical products	Protects specific product designs
Manufacturing equipment	Reactor, filtration, drying, and classification systems	May reduce cost or improve consistency
Analytical control	Methods for impurity or particle characterization	Supports regulatory release and quality systems

The patent estate is fragmented. Suppliers and formulators may hold country-specific patents, but many older process patents have expired or have limited practical blocking effect. Freedom-to-operate analysis must focus on the supplier’s production route, surface treatment, and intended product application rather than on the iron oxide molecule itself.

Are iron oxides listed in the Orange Book?

No. The FDA Orange Book lists approved drug products and associated patents and exclusivity information for pharmaceutical products, not ordinary excipients as standalone commercial products (U.S. Food and Drug Administration, 2024c).

Iron oxide suppliers therefore do not obtain Orange Book exclusivity for the colorant. A finished drug containing iron oxide may have Orange Book-listed patents covering its active ingredient, formulation, method of use, or delivery system, but those rights do not generally create an excipient monopoly.

Do Paragraph IV challenges apply?

Paragraph IV certification applies to patents listed for an approved drug product. It does not apply to an iron oxide excipient sold independently.

A generic drug containing the same iron oxide can challenge patents listed for the finished reference product if those patents cover the drug formulation or method of use. The challenge would be directed to the finished drug’s listed patents, not to the excipient’s chemical identity.

How large is the pharmaceutical iron oxide market?

Public market reports often combine iron oxides with broader pigment, colorant, specialty chemical, or excipient categories. They usually do not separate pharmaceutical-grade material from industrial and cosmetic grades.

The commercial market has three layers:

1. The global iron oxide pigment market, dominated by construction, coatings, plastics, and infrastructure.
2. High-purity and regulated iron oxide grades used in pharmaceuticals, cosmetics, food, and medical products.
3. Contract-specific pharmaceutical supply, where the supplier provides regulatory documentation and technical support.

The pharmaceutical segment is a small share of total iron oxide volume but has higher average selling prices because of:

• Tighter specifications.
• Regulatory documentation.
• Batch traceability.
• Customer qualification costs.
• Lower tolerance for color variation.
• More extensive change-control obligations.
• Longer approval cycles.

Price is usually less important than qualification continuity. A tablet manufacturer may accept a higher price to avoid revalidation, regulatory filing changes, or a visible color shift across millions of doses.

Which companies supply pharmaceutical-grade iron oxides?

The competitive field includes specialty pigment manufacturers, pharmaceutical excipient suppliers, and regional distributors. Supplier participation changes by geography and grade.

Relevant global and regional participants may include:

• Venator Materials PLC.
• LANXESS AG.
• Cathay Industries.
• Huntsman-derived pigment businesses and successor operations.
• Kremer Pigmente GmbH & Co. KG.
• Sensient Technologies Corporation.
• Colorcon, Inc., particularly in finished coating systems and formulation support.
• Asian producers supplying synthetic iron oxide grades and intermediates.
• Regional pharmaceutical excipient distributors and custom color suppliers.

The supplier landscape is not identical to the industrial pigment market. Pharmaceutical customers may source from a pigment manufacturer but buy through an excipient distributor or a coating-system provider.

Supplier selection typically depends on:

Criterion	Buyer concern
Regulatory status	Acceptability in the target market
Purity	Metals, soluble salts, and process residues
Color consistency	Batch matching and product appearance
Particle engineering	Dispersion and coating uniformity
Supply continuity	Dual sourcing and business continuity
Documentation	DMF support, certificates, audits, and change control
Manufacturing location	Tariffs, logistics, and geopolitical exposure
Technical service	Formulation troubleshooting and scale-up support

How strong is the patent estate for iron oxide excipients?

The patent estate is moderate for specialized manufacturing and weak for the underlying excipient.

Composition-of-matter strength

Low. Iron oxide compounds are old, widely produced, and not susceptible to new-molecule exclusivity.

Process-patent strength

Moderate in narrow areas. Patents may cover a specific precipitation sequence, oxidation condition, particle morphology, or surface-treatment method. Their value depends on whether competitors can produce equivalent grades through alternative processes.

Formulation-patent strength

Potentially moderate to strong for a narrowly claimed coating or delivery system. These patents protect the combination of iron oxide with polymers, plasticizers, solvents, or other excipients, not the colorant alone.

Trade-secret strength

High in some manufacturing operations. Reactor conditions, impurity-removal steps, particle classification, and color-matching methods may be maintained as confidential know-how rather than patented.

The most durable barriers are often customer qualification, regulatory history, and production consistency. These barriers can delay substitution even where no enforceable patent blocks a competing supplier.

What manufacturing and supply risks affect iron oxide excipients?

Iron oxide production depends on iron-containing feedstocks, acids, alkalis, energy, water, filtration, drying, and calcination. Cost exposure varies by production route.

Key risks include:

• Energy-price volatility for calcination and drying.
• Feedstock contamination by trace metals.
• Environmental restrictions on wastewater and solid residues.
• Plant shutdowns affecting qualified supply.
• Freight costs for low-value, high-volume grades.
• Export restrictions or customs delays.
• Qualification delays for alternative sources.
• Changes in particle size or color strength after process modifications.
• Raw-material shortages affecting yellow grades or specific morphologies.

Pharmaceutical customers generally hold safety stock but may not maintain large inventories because the material is inexpensive relative to the finished drug. This creates an asymmetry: inventory value is low, but a shortage can disrupt coating operations and delay batch release.

Dual sourcing is difficult when color matching, particle-size distribution, and regulatory documentation must remain equivalent. A substitute supplier may require laboratory testing, pilot coating, stability studies, and regulatory assessment before commercial use.

What financial factors determine the market trajectory?

The financial trajectory is tied to volume growth in oral solid dosage products and to the migration toward higher-documentation grades.

Demand drivers

• Growth in generic and branded tablets.
• Expansion of pharmaceutical manufacturing in India and China.
• Increased use of film coatings for product identification.
• Growth in capsule-based therapies.
• Demand for visually differentiated pediatric and geriatric products.
• More stringent supplier qualification and traceability requirements.
• Outsourcing of coating and excipient supply to specialized vendors.

Constraints

• Low dosage levels limit volume growth.
• Many products can use alternative colorants.
• Some manufacturers are reducing colorants in response to clean-label or formulation-simplification strategies.
• Industrial pigment oversupply can pressure prices in non-pharmaceutical grades.
• Customers may consolidate color systems to reduce inventory complexity.
• Finished-dose companies may reformulate to avoid a supplier-specific grade.

Margin structure

Pharmaceutical-grade material can generate higher margins than industrial pigment because customers pay for documentation and consistency. Margin expansion is limited by the availability of alternative suppliers and the relatively simple chemistry.

The strongest financial position is held by suppliers that sell a complete solution: colorant, coating premix, technical support, regulatory documents, and global supply. A commodity iron oxide producer has less pricing power than a supplier embedded in a validated tablet-coating platform.

How does iron oxide compare with other pharmaceutical colorants?

Attribute	Iron oxides	Titanium dioxide	Synthetic organic colors	Natural colorants
Color range	Red, yellow, black, brown	White, opacity	Broad and bright	Variable
Light stability	Generally strong	Strong	Varies	Often weaker
Heat stability	Generally strong	Strong	Varies	Often limited
Regulatory scrutiny	Moderate	High in some jurisdictions	Color-specific	Source and stability concerns
Patent dependence	Low	Low to moderate for treated grades	Moderate for specialty systems	Moderate for extraction and stabilization
Cost position	Competitive	Competitive	Varies	Often higher
Formulation use	Coatings and identification	Opacity and whitening	Brand differentiation	Clean-label positioning

Iron oxides benefit from strong opacity, stability, and familiar regulatory status. Their limitations include a narrow color palette and possible concerns about elemental impurities or formulation appearance.

What litigation and settlement risks exist?

Standalone iron oxide excipient litigation is generally less prominent than litigation involving active pharmaceutical ingredients, drug-device combinations, or branded formulations.

Potential disputes include:

• Patent infringement involving a proprietary particle-treatment process.
• Trade-secret disputes involving pigment synthesis.
• Contract claims over supply interruptions.
• Product-quality claims involving contamination or color variation.
• Antitrust or exclusivity disputes tied to long-term supply contracts.
• Finished-drug patent litigation where iron oxide is part of a claimed coating system.

Settlement agreements are more likely to arise from commercial supply disputes or finished-drug patent litigation than from ownership of the iron oxide compound. A generic manufacturer can usually change colorants if the finished product’s specification and regulatory filing permit the change, although the change may require regulatory assessment and manufacturing requalification.

What generic-entry risks exist for drugs containing iron oxides?

Iron oxide does not normally create a standalone barrier to generic entry. Generic-entry risk is determined by the active ingredient, dosage form, formulation, method of use, and listed patents for the reference product.

Iron oxide can affect generic development in narrower ways:

• Color matching may be required to meet product-identification expectations.
• A specific coating composition may be claimed in a formulation patent.
• A reference product may use a proprietary premix or surface-treated pigment.
• A supplier change may trigger comparative dissolution or stability work.
• Regional color-additive rules may limit substitution.

These are development and regulatory risks rather than conventional excipient exclusivity rights.

What is the outlook for pharmaceutical iron oxides?

The market outlook is stable to moderately positive in value terms. Volume growth should track oral-solid-dose production, while value growth should come from high-purity grades, technical services, and regulatory support.

The most attractive commercial segments are:

• Synthetic grades with narrow particle-size specifications.
• Global products requiring multi-jurisdiction documentation.
• Preblended film-coating systems.
• Low-heavy-metal and low-soluble-salt grades.
• Custom color matching for large pharmaceutical brands.
• Regional supply arrangements that reduce dependence on a single plant.

The principal downside risks are substitution, customer consolidation, and the ability of large industrial pigment producers to compete on price. Suppliers with pharmaceutical qualification systems and integrated coating technologies are better positioned than undifferentiated commodity producers.

Key Takeaways

• Iron oxides are pharmaceutical colorants used mainly in tablet coatings, capsules, and selected topical products.
• Red, yellow, and black grades are the principal commercial forms.
• The pharmaceutical segment is small relative to the total iron oxide pigment market but has higher quality and documentation requirements.
• Iron oxides do not have meaningful composition-of-matter exclusivity.
• Process patents, surface-treatment patents, trade secrets, and customer qualification create the main competitive barriers.
• Iron oxides are not independently listed in the FDA Orange Book, and Paragraph IV challenges do not apply to the excipient as a standalone product.
• FDA color-additive rules, the Inactive Ingredient Database, pharmacopeial standards, and regional colorant regulations determine market access.
• Financial reporting usually aggregates pharmaceutical grades with broader pigment or specialty-chemical businesses.
• Supply reliability, impurity control, color consistency, and regulatory documentation are more important than patent ownership.
• The strongest suppliers sell a qualified color-and-coating system rather than an undifferentiated iron oxide powder.

FAQs About Pharmaceutical Iron Oxides

Is iron oxide an active pharmaceutical ingredient?

No. Iron oxide is generally an inactive colorant used to improve product identification, appearance, opacity, or coating performance.

Can a pharmaceutical company switch from one iron oxide supplier to another?

Yes, but the change may require comparative testing, color matching, quality assessment, stability evaluation, and regulatory review depending on the product and jurisdiction.

Are red and yellow iron oxides interchangeable?

No. They differ in chemical form, color strength, particle characteristics, and formulation behavior. A substitution may change appearance, dispersion, coating uniformity, and regulatory documentation.

Does iron oxide create a generic-drug patent barrier?

Usually no. Generic entry is controlled by patents and exclusivity covering the active drug and finished formulation. Iron oxide can create technical or regulatory work but rarely provides standalone exclusivity.

Are pharmaceutical iron oxides subject to heavy-metal controls?

Yes. Pharmaceutical manufacturers typically control elemental impurities, soluble salts, and other process residues through supplier specifications, testing, qualification, and change-control procedures.

References

European Commission. (2024). Food additives database: E172 iron oxides and hydroxides. https://food.ec.europa.eu

U.S. Food and Drug Administration. (2024a). Color additives permitted for use in drugs: 21 C.F.R. §§ 73.1200 and 73.200. https://www.ecfr.gov

U.S. Food and Drug Administration. (2024b). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book